Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alamar Biosciences, Inc. (ALMR) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $28.78, with a market capitalisation of $1.94B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $18.85 to $38.54. This page covers its latest market performance, valuation, price trends and company information.
$1.94B | |
$28.01 | |
$38.54 | |
$18.85 | |
$27.99 | |
394.80K | |
343.71K | |
-- | |
$38.54 | |
$18.85 | |
-- | |
-- |
Alamar Biosciences, Inc. (ALMR) is trading at $27.92 in pre-market trading as of 2026-09-15 23:31:00, down 0.25% ($0.07) from the previous close of $27.99
Pre-market trading shows how investors are pricing ALMR before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Alamar Biosciences, Inc. (ALMR) moved from $30.80 to $28.78, representing a decline of 6.56% ($2.02).
The stock traded between $27.25 and $31.06 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 296.62 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.4%
ALMR is currently trading at $28.78, placing it 50.4% of the way from its 52-week low of $18.85 to its 52-week high of $38.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alamar Biosciences, Inc. (ALMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.